文献速递炎症性肠病

前瞻性研究:受孕及妊娠期间使用硫嘌呤与不良妊娠结局或婴儿一岁时健康无关

Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-03-22

该前瞻性队列研究纳入荷兰三级健康中心2008年12月至2016年5月IBD孕前门诊的309例确诊IBD女性,共311次活产妊娠,其中108次妊娠(35%)使用硫嘌呤。校正诊断、生育治疗和疾病活动后,硫嘌呤使用与自然流产无关,出生结局相似,婴儿1岁时中位生长、感染数、过敏、疫苗接种不良反应或慢性病均无差异。

要点

  • 309例确诊IBD女性共311次活产妊娠,108次妊娠(35%)使用硫嘌呤。
  • 校正混杂因素后,硫嘌呤使用与自然流产无关联,出生结局相似。
  • 婴儿1岁时生长、感染、过敏、疫苗反应及慢性病无差异。

核心结论

  • 该前瞻性队列研究未发现妊娠期母亲使用硫嘌呤与自然流产增加、不良出生结局或婴儿1岁时不良健康结局存在关联。

研究设计与样本

  • 前瞻性队列研究,纳入荷兰三级健康中心2008年12月至2016年5月IBD孕前门诊的所有女性,孕前咨询并妊娠期每两月随访。
  • 共309例确诊IBD女性(216例克罗恩病、85例溃疡性结肠炎、8例IBD未分型),232例女性的311次妊娠活产,108次妊娠(35%)使用硫嘌呤。
  • 比较使用与未使用硫嘌呤女性的妊娠结局、出生结局及婴儿1岁时健康结局,并与同地区无IBD母亲所生婴儿比较健康结局。

主要发现

  • 校正诊断、生育治疗和疾病活动后,硫嘌呤使用与自然流产无关联。
  • 使用与未使用硫嘌呤的女性出生结局相似。
  • 婴儿1岁时,使用与未使用硫嘌呤女性所生婴儿之间、以及IBD与无IBD母亲所生婴儿之间,中位生长、感染数、过敏、疫苗接种不良反应或慢性病均无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Most data on the safety of thiopurine therapy for inflammatory bowel disease (IBD) during pregnancy come from retrospective studies, which makes it difficult to adjust for confounding factors. We performed a prospective cohort study to determine whether thiopurine use affects pregnancy outcomes or health outcomes of children. METHODS: We performed a prospective study of all women who visited the IBD preconception outpatient clinic at our tertiary health center in The Netherlands from December 2008 through May 2016. Patients were counseled before pregnancy and seen bimonthly during pregnancy. We collected and analyzed data on medication use, as well as lifestyle and clinical factors, during conception and pregnancy. Pregnancy outcomes (live birth, spontaneous abortion, elective abortion, and stillbirth), birth outcomes (gestational age, birth weight, and congenital abnormalities), and health outcomes of infants 1 year after birth were compared between women who did and did not use a thiopurine during conception and pregnancy. In addition, health outcomes of infants 1 year after birth were compared with infants born to mothers without IBD from the same geographic region. RESULTS: Our study comprised 309 women with confirmed IBD (216 with Crohn's disease, 85 with ulcerative colitis, and 8 with IBD unclassified). During the study period, 311 pregnancies of 232 women resulted in a live birth; a thiopurine was used during 108 pregnancies (35%). After correction for diagnosis, fertility treatment, and disease activity, there was no association between thiopurine use and spontaneous abortions. Birth outcomes were similar between women who did and did not use a thiopurine. Among infants 1 year of age, there were no differences in median growth, number of infections, allergies, adverse reactions to vaccinations, or chronic diseases between those born to women who did and did not use a thiopurine or between women with and without IBD. CONCLUSIONS: In this prospective cohort study, we found no association between maternal thiopurine use during pregnancy and increased spontaneous abortions, adverse birth outcomes, or adverse health outcomes of infants 1 year after birth.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kanis SL, de Lima-Karagiannis A, de Boer NKH, et al. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study. Clin Gastroenterol Hepatol. 2017. PMID: 28342949. doi:10.1016/j.cgh.2017.02.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。